Horizons: Perspectives on Psychedelics

Credentials, Clinics, and Costs: Stakeholders Respond to HRSA’s Psychedelic Therapy RFI

Scoop: Johnson & Johnson to Lead Delix Therapeutics’ $85M Series C

Paving the Way: Husseini Manji on Spravato’s Lessons for Psychedelic Drug...

Josh Lipson, PhD & Roman Palitsky, MDiv, PhD: Psychedelic Harms and...

Why Perimenopause Belongs in Psychedelic Research

The Psychedelic Practitioner Issue 6: Preparedness (People)

Two Years After Rejection, Resilient Quietly Refiles MDMA for PTSD Application

Smooth Sailing: Definium’s LSD Voyage Hits Primary and Key Secondary Endpoints...

Weekly Psychedelic Policy Briefing – August 9, 2026

Load more